XYNGARITM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events - Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla ...

XYNGARITM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events - Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla ...

The Company's lead product candidate, XYNGARI™, is currently in Phase 3 and is the Company's first product candidate being developed from its Spongilla technology platform. XYNGARI™ is a ...